A leader in oncology andinflammation
At Amgen, we lead with action. Our world-class inflammation and oncology franchises have a laser-like focus on improving the lives of patients with life-threatening or chronic diseases.
Offering biosimilars for the treatment of these diseases is one way we’re striving to improve patients’ lives. Biologic treatments for oncology and inflammation have changed the outlook for people with these diseases and everyone who cares for them.
Biologics in oncology
At Amgen, we are developing innovative medicines for novel targets in difficult-to-treat cancers. We are proud of our deep and diverse pipeline of leading-edge, first-in-class therapeutic approaches aimed to dramatically improve outcomes. And now, we are proud to apply this expertise to the development of biosimilar medicines for oncology patients.
Our biologics for cancer treatment include:
- A biologic treatment used in the curative setting
- Targeted therapies
- These include monoclonal antibodies (mAbs), which revolutionized cancer treatment and continue to constitute an important treatment modality.1
Our history with oncology biologics includes not only the discovery, development, and production of these practice-changing medicines, but also our innovative delivery systems to help increase treatment choices and adoption.
Biologics for chronic inflammatory diseases
Biologics for chronic inflammatory diseases, such as moderate to severe rheumatoid arthritis, were a true advance. With their advent, the provider's treatment plan for their patients was no longer just about managing symptoms, but about potentially putting the disease into clinical remission by inhibiting specifically targeted biochemical pathways of inflammation.2
Amgen has been at the forefront of innovator biologic medicines for inflammation for over 20 years. Now we have a pipeline that is rich in biosimilars that treat inflammation.
References: 1. Shuptrine CW, Surana R, Weiner LM. Monoclonal antibodies for the treatment of cancer. Semin Cancer Biol. 2012;22:3-13. 2. Keyser FD. Choice of biologic therapy for patients with rheumatoid arthritis: the infection perspective. Curr Rheumatol Rev. 2011;7:77-87.